Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its audited results for the year ended 31 December 2025. The Group reported revenue growth of 7% (6% in constant currency) to $3.349 billion, compared to $3.127 billion in 2024 with growth in all three geographies, North America, MENA, and Europe. Said Darwazah, […] The post Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes appeared first on Web-Release.
Breaking News:
- Meet Vida Aljada
- Indulge in Oliva’s Afternoon Tea at Marriott Hotel Al Forsan
- Tenable Highlights Agentic AI-Driven Exposure Management at GISEC Global 2026
- Abu Dhabi Student’s AI Triage Platform That Guides Patients to Right Care Wins Top Prize
- Khalifa Fund calls on Emirati founders to apply for NEXUS Programme
- Cloudera and Mistral Partner to Bring Specialized, Sovereign Intelligence to Enterprise Data
- Shufti Launches Transaction Trust Monitoring With an AI Rule Builder That Turns Plain-English Risk Scenarios Into Validated, Backtested Rules
- RAMINVEST HOLDING Advances Mauritania Gold Exploration Following 50.14 g/t Gold Assays at Wompou Project
Saturday, September 12